🇺🇸 FDA

Intelligence · Clinical Pipeline

Takeda Pipeline

All ClinicalTrials.gov programs at Takeda — phase, modality, and trial IDs.

Programs
335

Quick answer

Takeda has 335 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. TAK-280

    Takeda

    Unresectable Locally Advanced or Metastatic Cancer

    phase 2 small molecule terminated

    1 trial

  2. TAK-280, SILTUXIMAB, TOCILIZUMAB, TOCILIZUMAB, SILTUXIMAB, TOCILIZUMAB

    Takeda

    Unresectable Locally Advanced or Metastatic Cancer

    phase 2 small molecule active

    1 trial

  3. TAK-341

    Takeda

    Multiple System Atrophy

    phase 2 small molecule completed

    1 trial

  4. TAK-360

    Takeda

    Idiopathic Hypersomnia

    phase 2 small molecule active

    1 trial

  5. TAK-360

    Takeda

    Narcolepsy Type 2

    phase 2 small molecule active

    1 trial

  6. TAK-379

    Takeda

    Diabetes Mellitus

    phase 2 small molecule terminated

    1 trial

  7. TAK-385

    Takeda

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  8. TAK-385

    Takeda

    Uterine Fibroids

    phase 2 small molecule completed

    1 trial

  9. TAK-411

    Takeda

    Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

    phase 2 mab active

    1 trial

  10. TAK-442

    Takeda

    Venous Thromboembolism

    phase 2 small molecule completed

    1 trial

  11. TAK-442

    Takeda

    Acute Coronary Syndrome

    phase 2 small molecule completed

    1 trial

  12. TAK-448

    Takeda

    Low Testosterone

    phase 2 small molecule terminated

    1 trial

  13. TAK-448

    Takeda

    Hypogonadotropic Hypogonadism

    phase 2 small molecule terminated

    1 trial

  14. TAK-500

    Takeda

    Pancreatic Cancer

    phase 2 small molecule terminated

    1 trial

  15. TAK-505

    Takeda

    Malignant Solid Tumors

    phase 2 small molecule active

    1 trial

  16. TAK-583

    Takeda

    Diabetic Neuropathies

    phase 2 small molecule completed

    1 trial

  17. TAK-653

    Takeda

    Treatment-Resistant Depression

    phase 2 small molecule terminated

    1 trial

  18. TAK-659

    Takeda

    AML

    phase 2 small molecule terminated

    1 trial

  19. TAK-662

    Takeda

    Congenital Protein C Deficiency

    phase 2 small molecule completed

    1 trial

  20. TAK-700

    Takeda

    Prostate Cancer

    phase 2 small molecule completed

    1 trial

  21. TAK-715 and methotrexate

    Takeda

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  22. TAK-755

    Takeda

    Acute Ischemic Stroke

    phase 2 mab active

    1 trial

  23. TAK-783 and methotrexate

    Takeda

    Arthritis, Rheumatoid

    phase 2 small molecule completed

    1 trial

  24. TAK-788

    Takeda

    Non-Small Cell Lung Cancer (NSCLC)

    phase 2 small molecule terminated

    1 trial

  25. TAK-788

    Takeda

    Carcinoma, Non-Small-Cell Lung

    phase 2 small molecule active

    1 trial

  26. TAK-850

    Takeda

    Influenza Prevention

    phase 2 small molecule terminated

    1 trial

  27. TAK-850

    Takeda

    Influenza Infection

    phase 2 mab completed

    1 trial

  28. TAK-850

    Takeda

    Influenza

    phase 2 small molecule completed

    1 trial

  29. TAK-850 0.5 mL injection

    Takeda

    Influenza Infection

    phase 2 small molecule completed

    1 trial

  30. TAK-853

    Takeda

    Ovarian Cancer

    phase 2 small molecule active

    1 trial

  31. TAK-906 Maleate

    Takeda

    Diabetes Mellitus and Gastroparesis, Idiopathic Gastroparesis

    phase 2 small molecule completed

    1 trial

  32. TAK-906 Maleate

    Takeda

    Diabetic Gastroparesis

    phase 2 small molecule completed

    1 trial

  33. TAK-919

    Takeda

    Coronavirus Disease (COVID-19)

    phase 2 mab completed

    1 trial

  34. TAK-931

    Takeda

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial

  35. TAK-935

    Takeda

    Epilepsy

    phase 2 small molecule completed

    2 trials

  36. TAK-935

    Takeda

    Developmental and/or Epileptic Encephalopathies

    phase 2 small molecule completed

    1 trial

  37. TAK-951

    Takeda

    Postoperative Nausea and Vomiting (PONV)

    phase 2 small molecule completed

    1 trial

  38. TAK-954

    Takeda

    Diabetic Gastroparesis

    phase 2 small molecule completed

    1 trial

  39. TAK-954

    Takeda

    Critical Illness

    phase 2 small molecule terminated

    1 trial

  40. TAK-954 Placebo

    Takeda

    Postoperative Gastrointestinal Dysfunction

    phase 2 small molecule completed

    1 trial

  41. TAK-981

    Takeda

    Relapsed and/or Refractory Multiple Myeloma (RRMM)

    phase 2 small molecule terminated

    1 trial

  42. TAK-981

    Takeda

    Advanced or Metastatic Solid Tumors

    phase 2 small molecule completed

    1 trial

  43. TAK-981

    Takeda

    Lymphoma, Non-Hodgkin

    phase 2 small molecule terminated

    1 trial

  44. TAK-981

    Takeda

    Neoplasms

    phase 2 small molecule terminated

    1 trial

  45. TAK-994

    Takeda

    Narcolepsy Type 1 (NT 1)

    phase 2 small molecule terminated

    1 trial

  46. TAK-994

    Takeda

    Narcolepsy Type 1 (NT1)

    phase 2 small molecule terminated

    1 trial

  47. TAK228

    Takeda

    Lymphoma

    phase 2 small molecule terminated

    1 trial

  48. TD-8954

    Takeda

    Enteral Feeding Intolerance

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does Takeda have?

335 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.